<DOC>
	<DOCNO>NCT02245737</DOCNO>
	<brief_summary>The purpose study assess efficacy safety LY3314814 compare placebo administer 104 week treatment early Alzheimer´s disease . The study test hypothesis LY3314814 disease-modifying treatment participant early Alzheimer´s disease , define continuum participant mild cognitive impairment ( MCI ) due Alzheimer´s disease participant diagnose mild dementia Alzheimer´s type , measure change baseline 13-item Alzheimer 's Disease Assessment Scale - Cognitive Subscale ( ADAS-Cog13 ) score week 104 2 LY3314814 treatment group compare placebo .</brief_summary>
	<brief_title>An Efficacy Safety Study LY3314814 Early Alzheimer 's Disease</brief_title>
	<detailed_description>Participants meet study entry requirement require undergo either amyloid positron emission tomography ( PET ) scan lumbar puncture cerebrospinal fluid ( CSF ) sample screen document presence abnormal level brain CSF amyloid study inclusion . The study include 2 sub-studies : participant undergo PET scan screening include PET-substudy , participant undergo lumbar puncture screen include CSF substudy substudies complete .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Gradual progressive change participant 's memory function 6 month , report participant study partner MiniMental State Examination score 2030 inclusive screen Objective impairment memory evaluate memory test perform screen For diagnosis mild Alzheimer 's Disease ( AD ) , participant meet National Institute Aging Alzheimer 's Association ( NIAAA ) criteria probable AD For diagnosis MCI due AD , participant meet NIAAA criterion MCI due AD Significant neurological disease affect central nervous system , AD , may affect cognition ability complete study , include limited , dementias , serious infection brain , Parkinson´s disease , epilepsy recurrent seizure History clinically evident stroke , multiple stroke base history image result History clinically important carotid vertebrobasilar stenosis plaque History multiple concussion sustain cognitive complaint objective change neuropsychological function last 5 year Participants current Diagnostic Statistical Manual Mental Disorders , Fifth Edition diagnosis Major Depressive Disorder current primary psychiatric diagnosis AD , judgment investigator , psychiatric disorder symptom likely confound interpretation drug effect , affect cognitive assessment , affect participant´s ability complete study History alcohol drug abuse dependence ( except nicotine dependence ) within 2 year screen Within 1 year screen screen baseline , follow : myocardial infarction ; moderate severe congestive heart failure , New York Heart Association class III IV ; hospitalization , symptom , unstable angina ; syncope due orthostatic hypotension unexplained syncope ; know significant structural heart disease ( eg , significant valvular disease , hypertrophic cardiomyopathy ) , hospitalization arrhythmia Congenital QT prolongation History cancer within last 5 year , exception nonmetastatic basal and/or squamous cell carcinoma skin , situ cervical cancer , nonprogressive prostate cancer cancer lowrisk recurrence spread Current serious unstable clinically important systemic illness , judgment investigator , likely affect cognitive assessment , deteriorate , affect participant 's safety ability complete study , include hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , immunologic , hematologic disorder</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Neurogenerative Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Delirium , Dementia , Amnestic , Cognitive Disorders</keyword>
	<keyword>Tauopathies</keyword>
</DOC>